The firm announced revenue decreased from $838 million in the second quarter of last year to $633 million in this year's second quarter because of pandemic-related disruption in customers' operations, Illumina said.

Similarly, net income under generally accepted accounting principles (GAAP) for the quarter was $47 million, compared with $296 million in the same quarter last year.

On the nonGAAP side, net income was $92 million compared with $200 million for the same quarter in 2019.

Illumina launches affordable sequencing kit for labs
Illumina has launched its NovaSeq 6000 v1.5 reagent kit, intended to make genome sequencing more accessible and affordable for labs of all sizes with...

Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.

Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...

Imagia, Illumina partner to advance precision medicine
Healthcare artificial intelligence firm Imagia is partnering with Illumina on a project to further advance the development of precision medicine using...

Illumina acquires BlueBee to speed NGS
Illumina has acquired BlueBee, a Dutch genomics analysis software firm that originated as a spinoff from Delft University of Technology, in an effort...